Effectiveness of Transurethral Bulkamid Injections as an Adjunct to the AdVance XP Sling for Male Patients with Post-Prostatectomy Incontinence
Background/Objectives: Bulkamid® (Axonics, Irvine, CA, USA) is a non-particulate polyacrylamide hydrogel used in the treatment of urinary incontinence. While its effectiveness is well-documented in female stress urinary incontinence (SUI), there is limited data on its role in male stress urinary incontinence, particularly post-prostatectomy incontinence (PPI). This study evaluates the efficacy of Bulkamid as a primary or adjunctive treatment for male PPI. Methods: A retrospective chart review was conducted on male patients who developed PPI and underwent Bulkamid injections between 2016 and 2021. Data collected included pre- and post-procedure pad usage, the volume of Bulkamid injected, prior and subsequent incontinence treatments, and patient-reported satisfaction. Bulkamid was injected transurethrally in four quadrants near the vesicourethral anastomosis using a rigid cystoscope. Results: Twenty-one men with a history of radical prostatectomy (six open and fifteen robotic), including four who received adjuvant radiotherapy, were included. Fifteen underwent Bulkamid injection as a primary treatment, with five (33%) requiring repeat injections due to initial improvement. Eight (54%) subsequently underwent an AdVance XP® sling placement, while two (13%) required no further treatment. Six patients received Bulkamid as an adjunct to prior incontinence surgery, with 80% of post-sling patients reporting improved continence. Bulkamid was less effective in men with detrusor overactivity or prior radiation. Conclusions: Bulkamid demonstrated a higher success rate as an adjunct to the AdVance XP sling, with 80% of men experiencing improved continence. As a primary treatment for PPI, success was modest, with only 33% achieving improvement, often requiring repeat injections or conversion to a sling. Bulkamid presents a low-risk option for select male PPI patients, particularly those with prior sling placement, but durability and long-term effectiveness remain concerns.
Authors
- Joshua Makary (ORCID: https://orcid.org/0000-0002-2963-5849)
- L. Chan
- Vincent Tse (ORCID: https://orcid.org/0000-0002-0993-2176)
- Sophie Plagakis (ORCID: https://orcid.org/0000-0002-3253-1725)
- Thomas King (ORCID: https://orcid.org/0000-0002-6270-0999)
Institutions
- The University of Sydney (AU)
- Queen Elizabeth Hospital Birmingham (GB)
- Concord Repatriation General Hospital (AU)
- Canberra Hospital (AU)
- Macquarie University (AU)
Publication Details
- Journal
- Société Internationale d’Urologie Journal
- Published
- 2025-10-21
- DOI
- https://doi.org/10.3390/siuj6050063
- Primary Topic
- Pelvic floor disorders treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00